Radio and PodcastLive Radio & PodcastsLoading episode
Fetching episode details...
Radio and PodcastLive Radio & PodcastsRadio and PodcastLive Radio & PodcastsFetching episode details...
Radio and PodcastLive Radio & Podcasts
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? is an episode from GRACEcast by Howard (Jack) West, MD. The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug C...
This episode belongs to GRACEcast.
Use the player on this page to stream the episode online.
Published Jul 17, 2014, 07:28 long, audio available.
Continue listening to more episodes from GRACEcast.
Jul 29, 2014 - 01:55
Jul 24, 2014 - 02:03
Jul 20, 2014 - 04:40
Jul 15, 2014 - 03:15
Jul 13, 2014 - 07:22
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
You can listen to Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? online on Radio and Podcast. Open the player on this page to stream the available audio.
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? is an episode from GRACEcast by Howard (Jack) West, MD.
This episode is 07:28 long.
This episode was published on Jul 17, 2014.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from GRACEcast when more episodes are available from the podcast feed.